Durvalumab vs Rosuvastatin
Durvalumab vs Rosuvastatin: Overview
This comparison examines the pharmacological differences between Durvalumab and Rosuvastatin.
Mechanism of Action
Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.
Rosuvastatin: Competitive inhibitor of HMG-CoA reductase.
Pharmacokinetics
Half-life: Durvalumab β 17 days; Rosuvastatin β 19 hours.
Chemical Properties
Molecular Formula: Rosuvastatin β C22H28FN3O6S.
Molecular Weight: Rosuvastatin β 481.5390 g/mol.
Type: Durvalumab β Antibody; Rosuvastatin β Small molecule.